科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: Vascular endothelial growth factor (VEGF) genetic polymorphisms play important roles in the risk and prognosis of many solid tumors. However, in osteosarcoma, the results are conflicting. Thus, a systematic review and meta-analysis was performed to investigate the effects of VEGF polymorphisms on osteosarcoma risk and prognosis. Methods: A comprehensive search was carried out in electronic databases. Odds ratio (OR) with its 95% confidence interval (CI) were calculated for the extracted data. Results: Three case-control studies on risk, including 671 cases and 848 controls, and two retrospective cohort studies on prognosis, including 456 cases, were enrolled. Meta-analysis showed a significant association between the -634 G/C polymorphism and osteosarcoma risk (CC vs. GG (OR: 0.72, 95% CI=0.53-0.97); CC vs. GC+GG (OR: 0.76 95% CI=0.60-0.97)). In addition, a significant association between osteosarcoma risk and the +936 C/T polymorphism was indicated (TT vs. CC (OR: 1.75, 95% CI=1.15-2.59); CT+TT vs. CC (OR: 1.18, 95% CI=0.96-1.46)). Furthermore, polymorphism -2578 C/A, but not +1612 G/A or -1156 G/A, was also identified as a risk factor in the original research. For osteosarcoma prognosis, meta-analysis of the +936 C/T polymorphism showed no significant associations (CT vs. CC (OR: 0.58, 95% CI=0.08-4.19), TT vs. CC (OR: 0.50, 95% CI=0.04-6.03), CT+TT vs. CC (OR: 0.53, 95% CI=0.05-5.20) and TT vs. CT+CC (OR: 0.77, 95% CI=0.32-1.87)). Polymorphisms +1612 G/A and -634 G/C also had no effects on osteosarcoma prognosis. Conclusions: Our results indicated that VEGF polymorphisms might influence osteosarcoma risk, but had no associations with its prognosis.
- 出版日期2016
- 单位南京大学
